Trial · NCT00762710
Study of the Medication Prazosin for Alcohol Dependence
NCT00762710, Phase 2, Completed, Seattle Institute for Biomedical and Clinical Research; results first posted 2020-06-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of the Medication Prazosin for Alcohol Dependence. Trials, record NCT00762710. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00762710
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of the Medication Prazosin for Alcohol Dependence
- NCT number
- NCT00762710
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 92 participants, actual
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Conditions
- Alcoholism
- Interventions
- Prazosin medication, Placebo medication
- First posted
- 2008-09-30
- Last updated
- 2020-06-04
- Results first posted
- 2020-06-04
- Limitations and caveats
- Lack of knowledge of optimal dosing for prazosin and medication adherence (medication adherence was suboptimal).
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Alcohol Consumption | 12 weeks | At the baseline and final medication visits, the Form 90 (19) was used to assess alcohol and drug use for the preceding 90-day period |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Alcohol Consumption | 12 weeks | Providing baseline and last week of medication information for all participants that completed the titration period (40 in each group). | percentage of days heavy drinking | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Alcohol Consumption | Prazosin | Baseline % Days Heavy Drinking | 71.8 | Standard Deviation 29.1 | percentage of days heavy drinking |
| Alcohol Consumption | Placebo | Baseline % Days Heavy Drinking | 66.5 | Standard Deviation 26.0 | percentage of days heavy drinking |
| Alcohol Consumption | Prazosin | Final medication week % Days Heavy Drinking | 11.4 | Standard Deviation 22.8 | percentage of days heavy drinking |
| Alcohol Consumption | Placebo | Final medication week % Days Heavy Drinking | 22.6 | Standard Deviation 34.1 | percentage of days heavy drinking |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Prazosin | 48 | |
| Overall Study | STARTED | Placebo | 44 | |
| Overall Study | COMPLETED | Prazosin | 27 | |
| Overall Study | COMPLETED | Placebo | 29 | |
| Overall Study | NOT COMPLETED | Prazosin | 21 | |
| Overall Study | NOT COMPLETED | Placebo | 15 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Drowsiness | General disorders | Prazosin | 28 | 48 | |
| other | Drowsiness | General disorders | Placebo | 15 | 44 | |
| serious | Death | Psychiatric disorders | Prazosin | 0 | 48 | 0 |
| serious | Death | Psychiatric disorders | Placebo | 1 | 44 | 1 |
| serious | Medical hospitalization | Infections and infestations | Prazosin | 1 | 48 | 1 |
| serious | Medical hospitalization | Infections and infestations | Placebo | 0 | 44 | 0 |
| serious | medical hospitalization | Gastrointestinal disorders | Prazosin | 0 | 48 | 0 |
| serious | medical hospitalization | Gastrointestinal disorders | Placebo | 1 | 44 | 1 |
| serious | inpatient alcohol detoxification | Psychiatric disorders | Prazosin | 2 | 48 | 2 |
| serious | inpatient alcohol detoxification | Psychiatric disorders | Placebo | 0 | 44 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Prazosin | 0 | 48 |
| Total, all-cause mortality | Placebo | 1 | 44 |
| Total, other adverse events | Prazosin | 28 | 48 |
| Total, other adverse events | Placebo | 15 | 44 |
| Total, serious adverse events | Prazosin | 3 | 48 |
| Total, serious adverse events | Placebo | 2 | 44 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AA017184 | Clinical Trials of the Adrenergic a-1 Antagonist Prazosin for Alcohol Dependence | SIMPSON, TRACY L. | SEATTLE INST FOR BIOMEDICAL/CLINICAL RES | NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM | 2008 to 2012 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Prazosin vs Placebo: deaths from any cause | Trial comparisons |
| Prazosin vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00762710
GET https://conductscience.org/api/trials/v1/NCT00762710/registered